Rep. Gilbert Ray Cisneros, Jr. Buys STERIS plc (NYSE:STE) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of STERIS plc (NYSE:STE). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in STERIS stock on April 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.

STERIS Stock Up 5.1%

Shares of STE stock traded up $10.21 on Tuesday, hitting $212.06. The stock had a trading volume of 1,062,608 shares, compared to its average volume of 775,769. The firm has a market capitalization of $20.80 billion, a price-to-earnings ratio of 29.62 and a beta of 0.95. The stock’s 50 day moving average is $222.37 and its 200-day moving average is $243.74. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.59 billion. During the same period last year, the firm earned $2.74 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, research analysts expect that STERIS plc will post 10.22 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s payout ratio is presently 35.15%.

More STERIS News

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: STERIS issued fiscal 2027 EPS guidance of $11.10–$11.30, above Wall Street expectations, and also forecast revenue growth of 7%–8%, signaling continued demand for its sterilization and medical equipment businesses.
• Positive Sentiment: The board approved a new $1 billion share repurchase program, which can support the stock by reducing share count over time and suggesting management sees value in the shares.
• Positive Sentiment: Full-year fiscal 2026 revenue from continuing operations rose 9% to $5.9 billion, with 7% organic constant-currency growth, showing the core business is still expanding.
• Neutral Sentiment: The company missed fourth-quarter earnings and revenue estimates by a small margin, reporting $2.83 EPS versus $2.86 expected and revenue of $1.59 billion versus roughly $1.61 billion expected.
• Neutral Sentiment: Recent institutional and congressional trading data is mixed, with several hedge funds reducing positions but some notable buyers and multiple congressional purchases; these flows are not likely the main driver of today’s move.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in STERIS by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock valued at $3,114,882,000 after acquiring an additional 73,014 shares during the last quarter. State Street Corp boosted its stake in STERIS by 6.0% during the 4th quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after acquiring an additional 260,001 shares during the last quarter. Geode Capital Management LLC boosted its stake in STERIS by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock valued at $637,259,000 after acquiring an additional 14,151 shares during the last quarter. Orbis Allan Gray Ltd boosted its stake in STERIS by 5.6% during the 4th quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock valued at $570,296,000 after acquiring an additional 120,200 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in STERIS by 37.2% during the 4th quarter. AQR Capital Management LLC now owns 1,623,234 shares of the medical equipment provider’s stock valued at $411,522,000 after acquiring an additional 440,164 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

STE has been the topic of several recent analyst reports. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Weiss Ratings downgraded STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, April 16th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $275.20.

Insider Transactions at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director directly owned 705 shares in the company, valued at $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.07% of the stock is owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.